RESEARCH ARTICLE

Bisphosphonate Use and Risk of Implant Revision after Total Hip/Knee Arthroplasty: A Meta-Analysis of Observational Studies

Songsong Teng¹,², Chengqing Yi¹*, Christian Krettek², Michael Jagodzinski³

¹ Department of Orthopedics, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai, P. R. China, ² Department of Orthopedic Trauma, Hannover Medical School, Hanover, Germany, ³ Department of Orthopedic Trauma, Agaplesion ev. Hospital Bethel, Bückeburg, Germany

* ycq3000@126.com

Abstract

Objective

Several studies investigated the association between bisphosphonate use and the risk of implant revision after total hip or knee arthroplasty (THA or TKA); However, the findings were inconsistent. We performed this meta-analysis to evaluate the overall relative risk of such an event.

Methods

We searched the PubMed, EMBASE and Cochrane library databases to identify relevant publications on April 22, 2015. To calculate the pooled risk ratios (RRs) with 95% confidential intervals (CIs), a fixed- or random-effects model was applied based on the heterogeneity across studies.

Results

Three cohort studies and one case-control study were included in this meta-analysis. Compared with the bisphosphonate nonusers, the patients who used bisphosphonates for a long period of time had a significantly decreased risk of implant revision after THA/TKA (summary adjusted RR = 0.48, 95% CI: 0.38–0.61), and the summary adjusted RRs for the users who underwent THA and those who underwent TKA were 0.47 (95% CI: 0.36–0.61) and 0.45 (95% CI: 0.21–0.95), respectively.

Conclusions

Long-term use of bisphosphonates is correlated with a significantly decreased risk of implant revision after THA/TKA. However, due to limited number of the included studies, the findings of the present study should be treated with caution. More well-designed studies are required to further confirm our findings.
Introduction

Total joint arthroplasty (TJA) is a highly effective surgical procedure that contributes to excellent pain relief and great improvement in the joint function in the patients with end-stage osteoarthritis[1]. However, due to implant failure, some patients will require a revision surgery during their lifetime, which is more costly and has a worse clinical outcome than primary TJA [2]. Thus, great efforts should be made to increase the lifespan of the implants.

To our knowledge, aseptic loosening and related osteolysis are considered the most common causes for implant failure[3]. Bisphosphonates, a family of pharmacological compounds strongly inhibiting bone resorption by inactivating osteoclasts, are recommended as first line treatments for post-menopausal osteoporosis[4, 5]. It is reported that long-term use of bisphosphonates contributes to persistent antifracture and bone mineral density (BMD) increasing effects for 3–5 years after an initial 3–5 years of treatment[6]. Recently, some investigators suggest that bisphosphonates should be a treatment option for patients with osteogenesis imperfecta (OI) due to their effects on increasing BMD and reducing the risk of clinical fractures in patients with OI[7–9]. Besides, they have also been used to treat other musculoskeletal disorders, such as Paget's disease of bone[10], bone metastasis[11] and fibrous dysplasia[12]. Therefore, they may have the potential to prevent periprosthetic bone resorption. Recently, various investigations including meta-analyses and randomized controlled trials (RCTs) have demonstrated that bisphosphonates can increase periprosthetic bone mineral density (BMD) and reduce periprosthetic bone loss and prosthetic migration[13–15]. However, there are still no RCTs that determine the effect of bisphosphonates on implant survival.

Recently, several observational studies have identified the association between bisphosphonate use and risk of implant revision after total hip or knee arthroplasty (THA or TKA) [16–19], but the outcomes have been inconsistent. For example, Prieto-Alhambra et al.[16] reported that the long-term use of bisphosphonates significantly reduced the risk of revision after THA/TKA, whereas Thillemann et al. [18] did not reveal a significant association. Therefore, we performed this meta-analysis to evaluate the association between bisphosphonate use and risk of implant revision after THA/TKA from observational studies.

Methods

Search strategy

We systematically searched PubMed, EMBASE and the Cochrane Library databases on April 22, 2015. The search terms were (bisphosphonate) AND (total hip arthroplasty OR total hip replacement OR total knee arthroplasty OR total knee replacement OR total joint arthroplasty OR total joint replacement). The search strategies are presented in S1 Table. The reference lists of all the retrieved articles were also consulted to find potentially relevant literatures.

Study selection criteria

The titles and abstracts were screened by two independent authors to identify the relevant studies. Then, full articles were read to employ the studies that met the following criteria: (1) used a cohort or case-control study design; (2) included participants undergoing THA or TKA; (3) used bisphosphonates before or after THA/TKA; (4) reported risk ratio (RR), hazard ratio (HR) or odds ratio (OR) with a 95% confidential interval (CI) or exhibited abundant data to calculate them; (5) English studies. Reviews, letters and conference abstracts that did not provide sufficient information were excluded.
Data extraction and quality assessment

The following data were independently extracted for every eligible study by two authors: surname of the first author, year of publication, study location, characteristics of the patients, crude and adjusted RRrs or HRrs with their 95% CIs, adjusted confounders and methods used for controlling the confounders.

Two independent reviewers assessed the methodological quality of the included trials using the Newcastle-Ottawa-Scale (NOS), considering the following domains: selection of study groups (4 scores), comparability of study groups (2 scores) and assessment of outcome (cohort study, 3 scores) or exposure (case-control study, 3 scores)[20]. Investigations with scores of 0–3, 4–6, 7–9 were respectively regarded as low, moderate and high quality. Any disagreement was resolved by consensus.

Statistical analysis

The RR was selected as the effect size to measure the association across studies. In the study that reported HR, we treated it as RR because HR is considered broadly equivalent to RR[21, 22]. The heterogeneity across studies was assessed using the Cochrane Q test and I² statistic. If no significant heterogeneity (p>0.1 and I<50%) existed, an inverse-variance fixed-effects model was utilized to pool the crude and adjusted RRrs with their 95% CIs among studies; Otherwise, a DerSimonian and Laird random-effects model was used to combine the data. Subgroup analysis was performed according to the adjustment for significant confounding factors. A sensitivity analysis was conducted to evaluate the stability of the results by omitting one study in each turn and pooling the data of the remaining studies. The publication bias was not assessed due to the small number of involved investigations (n<10)[23]. Data analysis was performed using RevMan Version 5.3 (Cochrane Collaboration, Oxford, UK). A p-value<0.05 was considered to be statistically significant.

Results

Literature search

The study selection process is exhibited in Fig 1. A total of 348 articles were identified by electronic searching. After 89 duplicates were removed, we screened the titles and abstracts of the remaining 259 articles. Afterwards, 233 articles were excluded because they were clearly irrelevant. After evaluating the remaining 26 publications in full, we excluded 22 articles because they did not report the data of implant revision. Finally, 4 studies were included in the present meta-analysis.

Study characteristics

The primary characteristics of the included studies are summarized in Table 1. There are 3 cohort studies and 1 case-control study. Although 2 of the cohort studies were performed by the same group, they were based on Danish and British populations, respectively. Thus, both of them were employed in this meta-analysis. The population-based case-control study was conducted in Denmark, and a total of 1 896 subjects (cases:632; controls: 1 264) were involved. Both crude and adjusted RRrs (HRrs) were available in all the studies, and the primary adjusted confounding factors were age, sex, body mass index, year of primary surgery, joint replaced, use of medications other than bisphosphonates and comorbid chronic disease.
Study quality and control of confounding in individual studies

The NOS was utilized to evaluate the study quality in the involved investigations. All 4 studies were high quality (S2 Table). However, because all the studies were observational, particular care was needed to examine confounding. Among them, matching was used to control the confounding in 2 studies during the study design stage, and multivariable analysis was performed in all the studies. Three studies were judged to have good control of confounding, and one study was judged to have limited control of confounding. However, in 3 of the 4 included studies, confounding by indications was likely. Baseline characteristics showed that bisphosphonate users had more comorbidities than nonusers. Moreover, bisphosphonate users were also more likely to be the users of calcium/vitamin D supplements. Residual confounders, such as smoking, physical activity, design of implant, can also contribute to the risk of bias.

Implant revision after THA/TKA

Fig 2 shows a forest plot presenting the association between bisphosphonate use and risk of all-cause revisions after THA/TKA. No heterogeneity was found across studies ($I^2 = 0\%$). Compared with nonusers, bisphosphonate users had a significantly decreased risk of revision surgery (summary adjusted RR = 0.48, 95% CI: 0.38–0.61). Sensitivity analysis was performed by omitting one study in each turn, analyzing the combined RRs for the rest studies. The overall adjusted RRs, ranging from 0.47 (95% CI: 0.35–0.63) to 0.53 (95% CI: 0.39–0.70), did not exhibit significant variation, indicating the stability of the outcome. When using crude data, the association was also found (summary crude RR = 0.46, 95% CI: 0.37–0.58), and sensitivity analysis revealed no significant variation.
Table 2 presents the outcomes of subgroup analysis according to the adjustment for significant confounding factors including age, gender, body mass index, smoking, type of implant fixation, year of primary surgery, location of surgery, use of calcium and vitamin D, use of medications other than bisphosphonates, number of visits to general practitioners and specialists, comorbidities, and adequacy of confounding control. Generally, for the results by fixed-effects model, the pooled RRs were similar to the overall RRs, and the significant association between bisphosphonate use and risk of implant revision after THA/TKA remained. However, we found
that the study that controlled the number of visits to general practitioners/specialists had a lower adjusted RR (0.41; 95% CI: 0.28, 0.61) than the studies that did not control it (adjusted RR = 0.53; 95% CI: 0.39–0.70), indicating that number of visits to general practitioners/specialists is a significant confounding factor that have to be adjusted because the patients who visit the practitioners/specialists more can undergo a better therapy.

Implant revision after TKA

The revision risk of TKA was documented in 2 studies. There was no heterogeneity between the 2 studies ($I^2 = 0$%). We found a significantly reduced risk of revision surgery in the bisphosphonate users than in nonusers (summary crude RR = 0.45, 95% CI: 0.26–0.78; summary adjusted RR = 0.45, 95%: 0.21–0.95) (Fig 3).

Implant revision after THA

The revision risk after THA was mentioned in all 4 studies. There was moderate heterogeneity across studies ($I^2 = 27\%, p = 0.25$). Meta-analysis using a fixed-effects model suggested bisphosphonate users had a significantly decreased risk of revisions than nonusers (summary adjusted RR = 0.47, 95% CI: 0.36–0.61) (Fig 4). We also performed a meta-analysis using a random-effects model due to the moderate heterogeneity with a $I^2 = 27\%$. The summary adjusted RR was 0.47 (95% CI: 0.35–0.65), reconfirming the significantly reduced risk in bisphosphonate users. Moreover, sensitivity analysis was carried out based on the method above. The pooled RRs by excluding any of the studies, ranging from 0.44 (95% CI: 0.31–0.64) to 0.54 (95% CI: 0.4–0.73), did not vary substantially, demonstrating the stability of the present outcome. The pooled crude RR is also significant (summary crude RR = 0.47, 95% CI:0.37–0.60) with no heterogeneity ($I^2 = 0$), and sensitivity analysis was conducted, yielding similar results.
Table 2. Subgroup analysis according to the adjustment for significant confounding factors.

| Adjustment for confounding | Level | No. of studies | $I^2$ (crude) | Crude RR (95% CI) | $I^2$ (adjusted) | Adjusted RR (95% CI) |
|----------------------------|-------|---------------|---------------|-------------------|-----------------|---------------------|
| Age > 40                   | Yes   | 3             | 12%           | 0.46 [0.36, 0.59] | 0               | 0.47 [0.36, 0.60]   |
|                            | No    | 1             | 0             | 0.45 [0.26, 0.77] | 0               | 0.58 [0.32, 1.05]   |
| Female > 60%               | Yes   | 2             | 0             | 0.41 [0.30, 0.56] | 0               | 0.46 [0.33, 0.64]   |
|                            | No    | 2             | 0             | 0.53 [0.38, 0.73] | 0               | 0.51 [0.37, 0.71]   |
| Body mass index            | Yes   | 2             | 0             | 0.53 [0.38, 0.73] | 0               | 0.51 [0.37, 0.71]   |
|                            | No    | 2             | 0             | 0.41 [0.30, 0.56] | 0               | 0.46 [0.33, 0.64]   |
| Smoking                    | Yes   | 1             | 0             | 0.41 [0.22, 0.76] | 0               | 0.54 [0.29, 0.99]   |
|                            | No    | 3             | 5%            | 0.47 [0.37, 0.60] | 0               | 0.47 [0.37, 0.61]   |
| Use of calcium and vitamin D| Yes  | 2             | 0             | 0.40 [0.29, 0.55] | 0               | 0.45 [0.32, 0.62]   |
|                            | No    | 2             | 0             | 0.53 [0.39, 0.73] | 0               | 0.52 [0.38, 0.73]   |
| Use of medications other than bisphosphonates | Yes | 3             | 0             | 0.41 [0.31, 0.54] | 0               | 0.47 [0.35, 0.63]   |
|                            | No    | 1             | 0             | 0.58 [0.40, 0.85] | 0               | 0.50 [0.34, 0.74]   |
| Number of visits to general practitioners/specialists | Yes | 1             | 0             | 0.39 [0.27, 0.57] | 0               | 0.41 [0.28, 0.61]   |
|                            | No    | 3             | 0             | 0.50 [0.38, 0.67] | 0               | 0.53 [0.39, 0.70]   |
| Year of primary surgery    | Yes   | 3             | 0             | 0.41 [0.31, 0.54] | 0               | 0.47 [0.35, 0.63]   |
|                            | No    | 1             | 0             | 0.58 [0.40, 0.85] | 0               | 0.50 [0.34, 0.74]   |
| Location of surgery        | Yes   | 2             | 0             | 0.43 [0.29, 0.65] | 0               | 0.56 [0.37, 0.86]   |
|                            | No    | 2             | 52%           | 0.48 [0.32, 0.70] | 0               | 0.45 [0.34, 0.60]   |
| Type of implant fixation   | Yes   | 2             | 0             | 0.53 [0.39, 0.73] | 0               | 0.52 [0.38, 0.73]   |
|                            | No    | 2             | 0             | 0.40 [0.29, 0.55] | 0               | 0.45 [0.32, 0.62]   |
| Comorbidities              | Yes   | 3             | 0             | 0.41 [0.31, 0.54] | 0               | 0.47 [0.35, 0.63]   |
|                            | No    | 1             | 0             | 0.58 [0.40, 0.85] | 0               | 0.50 [0.34, 0.74]   |
| Control of confounding     | Good  | 3             | 0             | 0.41 [0.31, 0.54] | 0               | 0.47 [0.35, 0.63]   |
|                            | Limited | 1             | 0             | 0.58 [0.40, 0.85] | 0               | 0.50 [0.34, 0.74]   |

doi:10.1371/journal.pone.0139927.t002

Fig 3. Forest plot of the association between bisphosphonate use and risk of implant revision after total knee arthroplasty (A: adjusted RR; B: crude RR).

doi:10.1371/journal.pone.0139927.g003
Preoperative bisphosphonate use and risk of revision after THA/TKA

Two studies analyzed the association between preoperative bisphosphonate use and risk of revision after primary TJA. Moderate heterogeneity existed between two studies ($I^2 = 49\%$, $p = 0.16$). Meta-analysis using a fixed-effects model suggested that the preoperative use of bisphosphonates did not reduce the risk of revision after THA/TKA (summary adjusted RR $= 0.97$, 95% CI: $0.79$–$1.19$) (Fig 5), which was consistent with the result of the meta-analysis using a random-effects model (summary adjusted RR $= 0.92$, 95% CI: $0.65$–$1.29$).

Discussion

In our meta-analysis of 3 cohort studies and 1 case-control study, bisphosphonate users had a significantly lower risk of implant revision after THA/TKA than nonusers when we pooled either crude RRs or adjusted RRs. The combined effect size for the patients who underwent THA was similar to that for those who underwent TKA.
To date, a variety of causes that contribute to implant failures after TJA have been identified [24–28]. A complication-based analysis using worldwide arthroplasty registers demonstrated that aseptic loosening was the most common cause for revisions both in THA (55.2%) and TKA (29.8%) [29]. Recently, a meta-analysis of RCTs suggested a protective effect of bisphosphonates on preventing periprosthetic bone loss after TJA [15], which could persist 18 to 72 months after discontinuation of bisphosphonates, and the second and third generation of bisphosphonates had a better efficacy than the first generation. Some investigators also reported that postoperative use of bisphosphonates significantly decreased implant migration after TJA [30, 31]. Recently, Sorenson et al. [32] demonstrated that bisphosphonate treatment enhanced early stability of revision joint replacements without preventing new bone formation. Furthermore, the use of bisphosphonates could increase the periprosthetic BMD around the whole stem and the cup by 2.4% and 7.1%, respectively, in the patients affected by periprosthetic osteolysis after THA, and there was a great improvement in pain and function, indicating that bisphosphonate treatment prevents wear debris mediated osteolysis [33]. All of these evidences suggest that the use of bisphosphonates after TJA may be beneficial for the prevention of osteolysis and stress shielding around the implants and finally reducing the prosthetic failure and revision surgery [19].

Among the studies included in the present meta-analysis, all 3 cohort studies reported that long-term use of bisphosphonates significantly decreased the risk of implant revision [16, 17, 19], whereas the case-control study showed a non-significant association, but the authors proposed that long-term use of bisphosphonate had a reduced risk of implant revision compared to short-term use [18], which is consistent with the outcomes in the study by Curtis et al. [34]. They demonstrated that short-term bisphosphonate treatment did not benefit bone strength. Because the authors of the cohort studies only defined the patients who underwent at least 182 days or 6 months of bisphosphonate treatment as bisphosphonate users, we extracted the crude and adjusted RR of revision for the patients who underwent more than 240 day treatment of bisphosphonates in the study conducted by Thillemann et al. [18] for meta-analysis. Our current investigation demonstrated that bisphosphonate users had a 52% lower risk of implant revision than nonusers. Although there was a higher effect estimate for the patients who had THA than those who had TKA in the study performed by Prieto-Alhambra et al. [16] in 2014, the pooled RRs of this meta-analysis showed a similar effect size for them, indicating bisphosphonates may have a similar effect on preventing the failures of THA and TKA. Besides the reduction of the risk of revision, use of bisphosphonates also significantly reduced the increased risk of fracture after THA/TKA [35]. Therefore, the use of bisphosphonates has a promising application potential for reducing implant failure and extending implant survival after THA/TKA. More importantly, this treatment is relatively costless and easy to handle, and the patients may be willing to accept this therapy, especially for the elderly, whose physical conditions cannot allow them to undergo a revision surgery. However, all the studies included in the meta-analysis were cohort studies. RCTs are required to evaluate the effectiveness of bisphosphonate treatment on the extension of implant survival.

Interestingly, in the present meta-analysis, we found that the patients who started the treatment of bisphosphonates preoperatively didn't have a lower risk of revision surgery compared to nonusers. It is still not very clear why preoperative bisphosphonate therapy does not benefit implant integration. Prieto-Alhambra et al. [16] inferred that preoperative use of bisphosphonates could reduce bone remodeling, which might prevent the regeneration of the underlying bone and harm osteointegration. In contrast, postoperative bisphosphonate treatment favors the reduction of inflammation-mediated osteolysis around implant and effectively inhibits aseptic loosening of prosthesis after TJA. In the study by Thillemann et al. [18], the authors found that the length of bisphosphonate use after THA was inversely correlated with the risk of
implant revision, and the patients who used the bisphosphonates for a short-time period had a significantly increased risk of implant revision due to deep infection, which was not observed in the patients undergoing a long-time treatment of bisphosphonates after THA. All these findings demonstrate that unreasonable use of bisphosphonates after TJA may lead to implant failure. In addition, long-term use of bisphosphonates may result in some severe side effects, such as esophageal cancer, osteonecrosis jaw and atrial fibrillation[36]. Some studies also demonstrated the progression of necrosis of the jaw even after bisphosphonate interruption[37]. To date, no consensus has been reached on the time limitation of bisphosphonate use. The optimal dose frequency, doze size and duration of bisphosphonate therapy remain to be determined to avoid severe adverse effects without reducing the efficacy. Nevertheless, large prospective cohort studies with adequate duration are necessary to further confirm this finding due to the moderate heterogeneity and limited number of the included studies (n = 2).

There are several limitations in this study. First, the included publications were observational studies, which cannot reveal causality, but provide information on associations. Compared with RCTs, observational studies have a lower level of evidence. Lack of more RCTs indicates our meta-analysis is based on rather limited evidence, which limits the quality of the meta-analysis. Second, the quality of the included studies varied. Although all the included studies controlled the primary confounders, the residual confounding, such as smoking, BMD of the patients, type of implants and amount of exercise after surgery, may still affect the association. For example, in one of our previous studies, we found that smoking may significantly increase the risk of all-cause revisions after THA[38]. This critical factor was not considered in most studies, and physical activity is a known risk factor for the aseptic loosening of the implants[39], whereas none of the authors takes it into account, which may result in the miscalculation of the outcomes. In our subgroup analysis, we found that number of visits to practitioners/specialists was a significant confounding required to be controlled. According to the baseline characteristics, confounding by indications may exist, and the bisphosphonate users were more likely to intake calcium/vitamin D supplements, which may also affect the overall RR. Moreover, moderate heterogeneity existed between studies. However, sensitivity analyses suggested that the outcomes of this meta-analysis were rather robust. Third, the small number of studies is a main limitation of this study, which may lead to a high risk of bias. Therefore, more prospective studies are needed to confirm the association.

Conclusions
The present meta-analysis suggests that long-term bisphosphonate use is associated with a significantly reduced risk of implant revision after THA/TKA. However, because of the limited number and varied quality of the included studies, these findings should be treated with caution, and more well-designed investigations, like RCTs, are required to validate our findings.

Supporting Information
S1 PRISMA Checklist.
(DOC)

S1 Table. Search strategy for PubMed on April 22, 2015.
(DOC)

S2 Table. Methodological quality of the studies included in the meta-analysis.
(DOC)
Author Contributions
Conceived and designed the experiments: ST CY CK MJ. Performed the experiments: ST CY. Analyzed the data: ST CY CK MJ. Contributed reagents/materials/analysis tools: ST CY. Wrote the paper: ST CY CK MJ.

References
1. Ethgen O, Bruyere O, Richy F, Dardenne C, Reginster JY. Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg Am. 2004; 86-A(5):963–974. Epub 2004/05/01. PMID: 15118039.
2. Li XA, Iyer S, Cross MB, Figgie MP. Total joint replacement in adolescents: literature review and case examples. Curr Opin Pediatr. 2012; 24(1):57–63. Epub 2012/01/17. doi: 10.1097/MOP.0b013e32834ec96a PMID: 22245907.
3. Havelin LI, Engesaeter LB, Espehaug B, Furnes O, Lie SA, Vollset SE. The Norwegian Arthroplasty Register: 11 years and 73,000 arthroplasties. Acta Orthop Scand. 2000; 71(4):337–353. Epub 2000/10/12. doi: 10.1080/000164700317393321 PMID: 11028881.
4. Hauk L. ACOG releases practice bulletin on osteoporosis. Am Fam Physician. 2013; 88(4):269–275. Epub 2013/08/16. PMID: 23944732.
5. Compston J, Bowring C, Cooper A, Cooper C, Davies C, Francis R, et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas. 2013; 75(4):392–396. Epub 2013/07/03. doi: 10.1016/j.maturitas.2013.05.013 PMID: 23810490.
6. Enoksen EF, Diez-Perez A, Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone. 2014; 58:126–135. Epub 2013/10/15. doi: 10.1016/j.bone.2013.09.023 PMID: 24120384.
7. Lindahl K, Langdahl B, Ljunggren O, Kindmark A. Treatment of osteogenesis imperfecta in adults. Eur J Endocrinol. 2014; 171(2):R79–90. Epub 2014/04/25. doi: 10.1530/eje-14-0017 PMID: 24760541.
8. Prieto-Alhambra D, Lalmohamed A, Abrahamsen B, Arden NK, de Boer A, Vestergaard P, et al. Oral bisphosphonate use and total knee/hip implant survival: validation of results in an external population-based cohort. Arthritis Rheumatol. 2014; 66(11):3233–3240. Epub 2014/07/23. doi: 10.1002/art.38789 PMID: 25047677.
based retrospective cohort study. BMJ. 2011; 343:d7222. Epub 2011/12/08. doi: 10.1136/bmj.d7222 PMID: 22147990; PubMed Central PMCID: PMCPMC3232250.

18. Thillemann TM, Pedersen AB, Mehneret F, Johnsen SP, Soballe K. Postoperative use of bisphosphonates and risk of revision after primary total hip arthroplasty: a nationwide population-based study. Bone. 2010; 46(4):946–951. Epub 2010/01/28. doi: 10.1016/j.bone.2010.01.377 PMID: 20102756.

19. Khatod M, Inacio MC, Dell RM, Bini SA, Paxton EW, Namba RS. Association of Bisphosphonate Use and Risk of Revision After THA: Outcomes From a US Total Joint Replacement Registry. Clin Orthop Relat Res. 2015. Epub 2015/04/22. doi: 10.1007/s11999-014-4263-4 PMID: 25896134.

20. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(8):603–605. Epub 2010/07/24. doi: 10.1007/s10654-010-9491-z PMID: 20652370.

21. de Lemos ML. How to survive the survival plots. Lancet. 2002; 360(9337):954. Epub 2002/10/02. doi: 10.1016/s0140-6736(02)11063-4 PMID: 12354506.

22. Spruance SL, Reid JE, Grace M, Samore M. Hazard ratio in clinical trials. Antimicrob Agents Chemother. 2004; 48(8):2787–2792. Epub 2004/07/27. doi: 10.1128/aac.48.8.2787–2792.2004 PMID: 15273082; PubMed Central PMCID: PMCPMC478551.

23. Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta-analyses. BMJ. 2011; 343:d7222. Epub 2011/12/08. doi:10.1136/bmj.d7222 PMID: 22147990; PubMed Central PMCID: PMCPMC3232250.

24. Sadoghi P, Pawelika W, Liebensteiner MC, Williams A, Leithner A, Label G. The incidence of implant fractures after total hip arthroplasty. Int Orthop. 2014; 38(1):39–46. Epub 2013/10/01. doi: 10.1007/s00264-013-2110-3 PMID: 24077887; PubMed Central PMCID: PMCPMC3890121.

25. Prokopetz JJ, Losina E, Reid MC, Wright J, Baran JA, Katz JN. Risk factors for revision of primary total hip arthroplasty: a systematic review. BMC Musculoskelet Disord. 2013; 14:251. Epub 2012/12/18. doi:10.1186/1471-2474-13-251 PMID: 23241396; PubMed Central PMCID: PMCPMC3541060.

26. Ravi B, Escott B, Shah PS, Jenkinson R, Chahal J, Bogoch E, et al. A systematic review and meta-analysis comparing complications following total joint arthroplasty for rheumatoid arthritis versus for osteoarthritis. Arthritis Rheum. 2012; 64(12):3839–3849. Epub 2012/11/30. doi:10.1002/art.37690 PMID: 23192790.

27. Sadoghi P, Barckman J, Bechtolde J, Soballe K, Baas J. Preclinical evaluation of zoledronate to maintain bone allograft and improve implant fixation in revision joint replacement. J Bone Joint Surg Am. 2013; 95(20):1862–1868. Epub 2013/10/18. doi: 10.2106/jbjs.j.01193 PMID: 19181970.

28. Friedl G, Radl R, Stihsen C, Rehak P, Aigner R, Windhager R. The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial. J Bone Joint Surg Am. 2009; 91(2):274–281. Epub 2009/02/03. doi:10.2106/jbjs.g.01193 PMID: 19181970.

29. Prieto-Alhambra D, Javaid MK, Judge A, Maskell J, Kiran A, de Vries F, et al. Fracture risk before and after total hip replacement in patients with osteoarthritis: potential benefits of bisphosphonate use. Arthritis Rheum. 2011; 63(4):992–1001. Epub 2011/04/01. doi: 10.1002/art.30214 PMID: 21452321.

30. Sorensen M, Barckman J, Bechtolde J, Soballe K, Baas J. Preclinical evaluation of zoledronate to maintain bone allograft and improve implant fixation in revision joint replacement. J Bone Joint Surg Am. 2013; 95(20):1862–1868. Epub 2013/10/18. doi: 10.2106/jbjs.j.01193 PMID: 24132360; PubMed Central PMCID: PMCPMC3798180.

31. Trevisan C, Nava V, Mattavelli M, Parra CG. Bisphosphonate treatment for osteolysis in total hip arthroplasty. A report of four cases. Clin Cases Miner Bone Metab. 2013; 10(1):61–64. Epub 2013/07/17. doi: 10.11138/ccmb/2013.10.1 PMID: 23588314; PubMed Central PMCID: PMCPMC3710013.

32. Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int. 2008; 19(11):1613–1620. Epub 2008/05/17. doi: 10.1007/s00198-008-0604-4 PMID: 18483689; PubMed Central PMCID: PMCPMC2574626.

33. Prieto-Alhambra D, Javaid MK, Judge A, Maskell J, Kiran A, de Vries F, et al. Fracture risk before and after total hip replacement in patients with osteoarthritis: potential benefits of bisphosphonate use. Arthritis Rheum. 2011; 63(4):992–1001. Epub 2011/04/01. doi:10.1002/art.30214 PMID: 21452321.

34. Sali P, Abdollahi M. Long term bisphosphonate use in osteoporotic patients: a step forward, two steps back. J Pharm Pharm Sci. 2012; 15(2):305–317. Epub 2012/05/15. PMID: 22579009.
37. Bilezikian JP. Osteonecrosis of the jaw—do bisphosphonates pose a risk? N Engl J Med. 2006; 355 (22):2278–2281. Epub 2006/12/01. doi: 10.1056/NEJMp068157 PMID: 17135582.

38. Teng S, Yi C, Krettek C, Jagodzinski M. Smoking and risk of prosthesis-related complications after total hip arthroplasty: a meta-analysis of cohort studies. PLoS One. 2015; 10(4):e0125294. Epub 2015/04/25. doi: 10.1371/journal.pone.0125294 PMID: 25909602; PubMed Central PMCID: PMC409354.

39. Flugsrud GB, Nordsletten L, Espehaug B, Havelin LI, Meyer HE. The effect of middle-age body weight and physical activity on the risk of early revision hip arthroplasty: a cohort study of 1,535 individuals. Acta Orthop. 2007; 78(1):99–107. Epub 2007/04/25. doi: 10.1080/17453670610013493 PMID: 17453400.